Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes

Br J Haematol. 2004 Oct;127(2):238-9. doi: 10.1111/j.1365-2141.2004.05185.x.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Cytarabine / administration & dosage
  • Granulocyte Colony-Stimulating Factor / administration & dosage
  • Humans
  • Idarubicin / therapeutic use
  • Leukemia / drug therapy*
  • Myelodysplastic Syndromes / drug therapy*
  • Vidarabine / administration & dosage
  • Vidarabine / analogs & derivatives

Substances

  • Anti-Bacterial Agents
  • Antineoplastic Agents
  • Cytarabine
  • Granulocyte Colony-Stimulating Factor
  • Vidarabine
  • Idarubicin

Supplementary concepts

  • FLAG protocol